EWTX - NASDAQ

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%

HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.90B

EPS-1.6300

P/E Ratio-22.21

Earnings Date08/06/2026

ewtx

Net Interest Income

Last Annual Value

23.61M

3-Year CAGR

169%

5-Year CAGR

221%

10-Year CAGR

60%

Adjust for Inflation

Edgewise Therapeutics, Inc. Competitors Analysis of Net Interest Income

EWTX · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Edgewise Therapeutics, Inc. NASDAQ:EWTX	23.61M	18.5%	125.8%	N/A
uniQure N.V. NASDAQ:QURE	-45.03M	N/A	N/A	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	16.95M	59.3%	N/A	N/A
Structure Therapeutics Inc. NASDAQ:GPCR	35.97M	N/A	N/A	N/A
Viridian Therapeutics, Inc. NASDAQ:VRDN	22.45M	10.3%	134.7%	N/A
Nuvation Bio Inc. NYSE:NUVB	7.75M	-32.0%	21.2%	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	28.61M	29.7%	124.2%	N/A
Janux Therapeutics, Inc. NASDAQ:JANX	44.04M	44.2%	179.8%	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	6.52M	N/A	N/A	N/A

Edgewise Therapeutics, Inc. Fair Value Envelope

EWTX · NASDAQ

Our analysis suggests that EWTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $36.21, this represents a potential HIDDEN relative to our calculated worth for Edgewise Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $36.21

Related Guides

Blog Categories

Continue your EWTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.